Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for
Article updated to note that BridgeBio sold a PRV for $110 million to an undisclosed buyer, Marinus won a PRV for its approval of ganaxolone, Biomarin has sold its third PRV for $110 million, and BioNTech has received a PRV for its Pfizer-partnered Covid-19 vaccine.
The system by which the FDA awards biopharma companies with priority review vouchers for new approvals of treatments for neglected tropical diseases, rare pediatric diseases and medical countermeasures continues to thrive, more than a decade after it began.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.